Home » Newsletters » BioWorld

BioWorld

Jan. 28, 1993

View Archived Issues

LTI BEGINS PHASE III TRIAL

VERTEX FORMS SUBSIDIARY

SCICLONE PACT FOR HEPATITIS DRUG

SHAMAN COMPLETES IPO

MICROCARB COMPLETES IPO

JOB-SEEKERS FLOOD EMPLOYMENT FAIR

CHEMEX BEGINS TRIALS OF PSORIASIS DRUG

FDA OKS ION-CHANNEL BLOCKER TRIALS

BIOSURFACE COMPLETES IPO

ALKERMES RECEIVES ANOTHER PATENT

IMMUNOGEN PLANS PHASE III TRIAL

APPLIED IMMUNE DEAL WITH HAEMONETICS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...